Jeffrey M Zaleski

Author:

Jeffrey P. Zaleski

ISBN #:

0062514512

US Patent:

6828439, Dec 7, 2004

Filed:

Aug 20, 2001

Appl. No.:

09/913924

Inventors:

Jeffrey M. Zaleski - Bloomington IN
Diwan Singh Rawat - Bloomington IN

Assignee:

Advanced Research and Technology Institute, Inc. - Indianapolis IN

International Classification:

C07F 1100

US Classification:

546 2, 534 15, 540465, 540488, 546 10, 564374, 568729, 568807

Abstract:

Disclosed are novel compounds, compositions, and methods that are particularly useful in photodynamic therapy. In particular, the inventive compounds, compositions, and methods relate to the formation of cytotoxic radical species in the presence of light. Significantly, the compounds, compositions, and methods of the present invention do not require the presence of oxygen in the photodynamic therapy and, as such, rely on a unimolecular mechanism for producing the radicals. The inventive compounds, compositions, and methods can be used, for example, in the treatment of cancers as well as infections caused by microorganisms such as protozoa, fungi, bacteria, and viruses.

US Patent:

6987132, Jan 17, 2006

Filed:

Oct 10, 2002

Appl. No.:

10/268172

Inventors:

Jeffrey M. Zaleski - Bloomington IN, US
Diwan Singh Rawat - Bloomington IN, US

Assignee:

Advanced Research and Technology Institute, Inc. - Indianapolis IN

International Classification:

A61K 31/136
C07C 211/44

US Classification:

514646, 564305, 564280, 568 8, 568 62, 556 1, 514706

Abstract:

The invention provides novel tetradentate enediyne ligands that are themselves thermally stable, yet react at about room temperature or slightly higher upon addition of metal ions or under photothermal conditions. In another aspect of the invention, a method of treating a disorder in a mammal comprising administering a therapeutically effective amount of a compound or composition is provided. In addition, the free ligand can be delivered to the mammal prior to complexation to metals, such that the ligand is exposed to a metal in the body and forms a metal complex in vivo. Furthermore, a metal complex of the invention can be administered to the mammal such that the complex exchanges the first metal center with another endogenous metal in order to form a second metal complex in vivo. The second metal complex is capable of forming a benzenoid diradical under physiological conditions and/or under photothermal conditions.

US Patent:

7211603, May 1, 2007

Filed:

Sep 29, 2005

Appl. No.:

11/238231

Inventors:

Jeffrey M. Zaleski - Bloomington IN, US
Diwan Singh Rawat - Bloomington IN, US

Assignee:

Indiana University Research and Technology Corporation - Indianapolis IN

International Classification:

A61K 31/121
C07C 49/11

US Classification:

514678, 568308, 568 77, 568 75, 568 8, 514706

Abstract:

The invention provides novel tetradentate enediyne ligands that are themselves thermally stable, yet react at about room temperature or slightly higher upon addition of metal ions or under photothermal conditions. In another aspect of the invention, a method of treating a disorder in a mammal comprising administering a therapeutically effective amount of a compound or composition is provided. In addition, the free ligand can be delivered to the mammal prior to complexation to metals, such that the ligand is exposed to a metal in the body and forms a metal complex in vivo. Furthermore, a metal complex of the invention can be administered to the mammal such that the complex exchanges the first metal center with another endogenous metal in order to form a second metal complex in vivo. The second metal complex is capable of forming a benzenoid diradical under physiological conditions and/or under photothermal conditions.

US Patent:

6514995, Feb 4, 2003

Filed:

Sep 25, 2001

Appl. No.:

09/962388

Inventors:

Jeffrey M. Zaleski - Bloomington IN
Diwan Singh Rawat - Bloomington IN

Assignee:

Advanced Research and Technology Institute, Inc. - Indianapolis IN

International Classification:

A61K 3144

US Classification:

514332, 546 2, 546264

Abstract:

The invention provides novel tetradentate enediyne ligands that are themselves thermally stable, yet react at about room temperature or slightly higher upon addition of metal ions or under photothermal conditions. In another aspect of the invention, a method of treating a disorder in a mammal comprising administering a therapeutically effective amount of a compound or composition is provided. In addition, the free ligand can be delivered to the mammal prior to complexation to metals, such that the ligand is exposed to a metal in the body and forms a metal complex in vivo. Furthermore, a metal complex of the invention can be administered to the mammal such that the complex exchanges the first metal center with another endogenous metal in order to form a second metal complex in vivo. The second metal complex is capable of forming a benzenoid diradical under physiological conditions and/or under photothermal conditions.